Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522857 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL1882229 | 0.87 | GLA (0.52) | ALDH1A1HSD17B10LMNAMAPTTSHR | |
| SCHEMBL17603509 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL7431717 | 0.83 | MAOB (0.50) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL3276252 | 0.83 | KDM4E (0.57) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL5945907 | 0.82 | CNR2 (0.57) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL31422815 | 0.81 | ADORA2A (0.51) | ALDH1A1HSD17B10LMNAMAPTTSHR | |
| SCHEMBL21639499 | 0.81 | ALDH1A1 (0.51) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL25349018 | 0.78 | ALDH1A1 (0.40) | ALDH1A1HSD17B10LMNAMAPTL3MBTL1 | |
| SCHEMBL1368453 | 0.77 | DAO (0.47) | ALDH1A1HSD17B10LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| CN-114423757-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220259205-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114423757-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021011724-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| US-6869960-B2 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1470126-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | ITO FUMITAKA (JP) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064425-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER JAPAN INC. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | OGFRL1, OXER1, ORMDL3 | ALDH1A1 306/4885HSD17B10 1237/4885LMNA 2789/4885 |
| US-20220259205-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | ALDH1A1 3949/4885HSD17B10 3848/4885LMNA 1227/4885 |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | ALDH1A1 3949/4885HSD17B10 3848/4885LMNA 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.